Cardiff Oncology (CRDF)
(Delayed Data from NSDQ)
$2.34 USD
-0.03 (-1.06%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $2.35 +0.01 (0.43%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CRDF 2.34 -0.03(-1.06%)
Will CRDF be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CRDF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRDF
Take the Zacks Approach to Beat the Markets: Navios Maritime, Coinbase Global, Virtu Financial in Focus
Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates
CRDF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cardiff Oncology (CRDF) Is a Great Choice for 'Trend' Investors, Here's Why
Cardiff (CRDF) Stock Rallies 194% in a Month: Here's Why
Here's Why Momentum in Cardiff Oncology (CRDF) Should Keep going
Other News for CRDF
Cardiff Oncology to Present at the Jefferies Healthcare Conference
Cardiff Oncology's Onvansertib: A Speculative Buy With Promising Data
Cardiff Oncology to Present at Upcoming Investor Conferences in May
The $5 Phenoms: 3 Cheap Stocks That Could Skyrocket by 2028
Buy Rating Affirmed on Cardiff Oncology as Phase 2 Trial Shows Promise for Accelerated Approval